Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 all comers meta-analysis

Andreas (NOR-Solidarity)
  NCT04321616		 RCTremdesivirCOVID 19 all comerslow
43/58 ongoing
    Norwegian NOR study (remdesivir)
          NCT04321616    		 RCTremdesivirstandard of careCOVID 19 all comerssome concern
    		43/58 no results
      Chang Chen et al.
              ChiCTR2000030254      		 RCTfavipiravir umifenovir (arbidol)COVID 19 all comerssome concern
      		120/120 inconclusive
      • inconclusive 48 % increase in clinical improvement,clinical improvement (7-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
      ELACOI (Standard of care)
              NCT04252885      		 RCTumifenovir (arbidol)standard of careCOVID 19 all comerssome concern
      		16/7 inconclusive
        jRCTs041190120
                  jRCTs041190120        		 RCTfavipiravir favipiravir COVID 19 all comershigh
        		44/45 inconclusive
        • inconclusive 42 % increase in viral clearance ,viral clearance (time to event analysis only) (PE) but with a low degree of certainty due to high risk of bias
        Jun C
                  NCT04252274        		 RCTdarunavir cobicistatstandard of careCOVID 19 all comershigh
        		15/15 inconclusive
        • inconclusive 42 % decrease in viral clearance by day 7 (PE) but with a low degree of certainty due to high risk of bias
        Lou (FAVIPIRAVIR)
                  ChiCTR2000029544        		 RCTfavipiravir standard of careCOVID 19 all comerssome concern
        		10/10 inconclusive
        • inconclusive 82 % decrease in viral clearance ,viral clearance by day 14 (PE) with a moderate degree of certainty due to some concern in risk of bias
        NCT04310228-FAVI (Zhao)
                  ChiCTR2000030894        		 RCTfavipiravir tocilizumab COVID 19 all comerssome concern
        		-/- inconclusive
        • inconclusive 68 % decrease in radiologic improvement (14-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
        EPIC-SR unpublished
                  NCT05011513        		 RCTnirmatrelvir / ritonavir (Paxlovid)placeboCOVID 19 all comersNA
        		-/- inconclusive
          4 studies excluded by filtering options (0 RCT / 4 OBS)

          PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
          Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

           

          - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons